Travtec Expands Operations in Lancashire - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Travtec Expands Operations in Lancashire


Travtec, a packaging line solutions specialist, has opened a second facility close to its Leigh, Lancashire headquarters. This move is part of an investment to expand the company’s operations to meet continuing demand for its systems, particularly as the pharmaceutical industry prepares for the current and forthcoming track and trace legislation, including the 2017 European Falsified Medicines Directive.

The new 150 m2 offices will house Travtec’s administrative support services, allowing its original building to increase its operational space by 200 m2. Travtec will be able to further expand its product offering, with the introduction of the full range of Lixis inspection equipment, including a blister vision system and pinhole detector.

Travtec specializes in the design and manufacture of product handling systems for a wide range of industries, including GSK, AstraZeneca, Merck, Bristol-Myers Squibb and Johnson & Johnson. The company’s product handling, coding and inspection systems are designed to complement inkjet printers, labellers, print and apply and thermal transfer equipment. Travtec works in partnership with OEMs to develop innovative new applications for both existing products and those under development. Travtec’s subsidiary company, Sunala, is the UK and Eire distributor for the Wolke m600 thermal inkjet printer for the pharmaceutical sector.

“This is an important milestone in the continuing growth of Travtec, enabling us to keep pace with customer demands throughout Europe,” commented Travtec managing director, Harry Thomason, in a press statement. “The new facilities and additional space will help to ensure we continue to devise and bring to market quickly innovative solutions that help our customers increase efficiencies.”

Source: Travtec

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here